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Background: Community-acquired carbapenem-resistant Enterobacterales (CA-CRE) are an important threat.
Methods: In CRACKLE-2, we defined patients with CA-CRE as admitted from home, without pre-existing condi
tions, and a positive culture within 48 h of admission. Healthcare-associated CRE (HA-CRE) were those with the
lowest likelihood of community acquisition, not admitted from home and cultured >48 h after admission.
Specific genetic markers in carbapenemase-producing Klebsiella pneumoniae were evaluated through random
forest modelling.
Results: CA-CRE and HA-CRE were detected in 83 (10%) and 208 (26%) of 807 patients. No significant differ
ences were observed in bacterial species or strain type distribution. K. pneumoniae (204/291, 70%) was the
most common CRE species, of these 184/204 (90%) were carbapenemase producers (CPKP). The top three gen
etic markers in random forest models were kpi_SA15, fimE, and kpfC. Of these, kpi_SA15 (which encodes a chap
erone/usher system) was positively associated (OR 3.14, 95% CI 1.13–8.87, P = 0.026), and kpfC negatively
associated (OR 0.21, 95% CI 0.05–0.72, P = 0.015) with CA-CPKP.
Conclusions: Ten percent of CDC-defined CRE were CA. The true proportion of CA-CRE in hospitalized patients is
likely lower as patients may have had unrecorded prior healthcare exposure. The kpi_SA15 operon was asso
ciated with the CA phenotype.

Introduction
Enterobacterales are commonly encountered pathogens causing
community-associated infections, such as urinary tract infections.
More recently, ESBL-producing Enterobacterales have been in
creasingly associated with community-acquired (CA) infections
in the US and worldwide.1 Carbapenems are the preferred

treatment option for invasive ESBL-producing Enterobacterales
infections.2,3 Concerningly, carbapenem resistance is also increas
ingly observed in Enterobacterales.4,5 Several novel treatment
options have been developed recently to better treat infections
caused by carbapenem-resistant Enterobacterales (CRE).6–8
However, the costs, need for intravenous therapy, and concerns
over further resistance development, limit the use of these
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Patients and methods

Whole-genome sequencing and genomic analysis
Genomic analysis was limited to carbapenemase-producing K. pneumo
niae (CPKP). WGS methods and genomic analyses were described previ
ously.11 Briefly, Snippy was used to identify core SNPs from whole
genome sequences for each genome compared with the reference gen
ome NGST258_2 (GCA_000597905.1). DNA sequences identified as being
prophages, repeat regions, or regions of recombination were masked
from downstream analysis using PHASTER, MUMmer, and Gubbins, re
spectively.13–15 A maximum-likelihood phylogenetic tree was con
structed from the recombination-free alignment using RAxML (v8.2.12)
using a general time-reversible model of nucleotide substitution and
four discrete gamma categories of rate heterogeneity (GTRGAMMA).
Node support was estimated by bootstrapping with 500 replicates.
Clusters were defined as strains sharing <22 SNPs and a most-recent
common ancestor based on the phylogenetic tree.16 R package ‘circlize’
was used to visualize the phylogenetic tree.17

Patients

Statistical analysis

CRACKLE-2 was a prospective, observational, multicentre cohort study.11
For this analysis, patients were included from CRACKLE-2 who were hos
pitalized in participating US hospitals between 30 April 2016 and 31
August 2017 with CRE isolated from any anatomical site in a clinical cul
ture and who met criteria for CA-CRE or HA-CRE. Patients with CRE that
were susceptible to carbapenems upon centralized susceptibility testing
(‘unconfirmed CRE’) were excluded.11 The characteristics of the cohort
from which these patients have been selected have been previously de
scribed.11 Patients from 24 study sites were included.

Distributions across two groups were analysed using the Wilcoxon Rank
Sum test for continuous variables and Fisher’s exact or Pearson-χ2 tests
for categorical variables. P values <0.05 were considered statistically sig
nificant. The CRACKLE-2 desirability of outcome ranking (DOOR) was com
pared across groups, as previously described.11 Briefly, this outcome
assessed three deleterious events: lack of clinical response, prolonged
hospitalization (hospitalization ≥30 days after first positive culture or re
admission within 30 days), and adverse events (new renal failure and/or
Clostridioides difficile infection), in addition to survival at 30 days after the
index culture. The best outcome was defined as being alive without dele
terious events. The worst outcome was death. Two levels in-between
these two extremes were: alive with 1 event, and alive with 2 or 3 dele
terious events. Within the subset of patients with CPKP (n = 184), random
forest analysis for the purpose of variable selection was performed on
bacterial genetic markers with CA-CRE versus HA-CRE as the outcome.
Seventy-five markers were a priori hypothesized to be potentially asso
ciated with colonization based on literature review (Table S1, available
as Supplementary data at JAC Online). Of these 75 markers, 40 were
found in >95% or <5% of strains and were excluded from analyses.
Relative importance of variables in random forest models was deter
mined using mean decrease in Gini coefficient and mean decrease in ac
curacy over 10 models. Logistic regression was used to determine OR and
95% confidence intervals (CI) of the top three selected genes. SAS 9.4
(SAS Institute, Cary, NC) and R 4.1.1 (R Core Team, 2020) were used for
analyses.

Ethics
The Institutional Review Board (IRB) of each participating healthcare sys
tem approved this study. Need for informed consent was waived by each
participating IRB. The IRB approval reference number at the University of
North Carolina at Chapel Hill is 19-3032.

Clinical definitions
Infections were defined using standardized criteria, as previously de
scribed.11 As the collected data did not allow application of the criteria
outlined by the US Centers for Disease Control and Prevention, CA-CRE
were defined here by the presence of all of the following: admission
from home, index CRE culture date within 48 h of hospitalization, and ab
sence of five documented conditions that would increase the likelihood of
recent healthcare exposure (kidney disease, malignancy, liver disease,
immunocompromise, or pregnancy). For the purpose of these analyses,
HA-CRE were defined as those isolates with the lowest likelihood of com
munity acquisition: admission from a long-term care or acute healthcare
facility AND timing of index CRE culture more than 48 h after admission.
Patients who fell into neither the CA-CRE nor the HA-CRE category were
excluded from these analyses. Clinical data were obtained from electron
ic medical records, and outcomes were defined as previously described.11

Microbiology
Susceptibility to carbapenems was determined at local clinical laborator
ies following the manufacturer’s instructions for MicroScan (Beckman
Coulter, Atlanta, GA, US), Vitek®2 and Etest® (both bioMérieux,
Durham, NC, US), BD Phoenix™ and BBL™ discs (both Becton Dickinson,
Durham, NC, US), Sensititre (Thermo Fisher, Waltham, MA, US), and using
disc diffusion or in-house agar dilution tests. Carbapenem susceptibility
results were confirmed in two independent central research laboratories
using the Etest® and MicroScan. CRE isolates that tested susceptible to
carbapenems upon central testing (‘unconfirmed CRE’) were excluded
from this study.11
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Results
Clinical characteristics and outcomes
In CRACKLE-2, 807 unique patients with confirmed CRE were en
rolled during the study period. Of these, 83 (10%) and 208 (26%)
met the criteria for either CA-CRE or HA-CRE, respectively (Table 1
and Figure 1). Distinct variability in the proportions of HA-CRE and
CA-CRE of total CRE cases was observed between study sites
(Figure S1, available as Supplementary data at JAC Online).
Patients with CA-CRE were more likely to be admitted at a com
munity hospital; 28% of patients with CA-CRE were admitted at a
community hospital, as compared with 13% of patients with
HA-CRE (P < 0.01). The distribution of sources between CA-CRE
and HA-CRE was significantly different, P < 0.001; the urine was
a more common source for CA-CRE (65% versus 25% in
HA-CRE), whereas HA-CRE were more frequently isolated from
the respiratory tract (40% versus 7% in CA-CRE). As expected,
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agents, especially in empirical antibiotic regimens. There are sev
eral reports of CA-CRE causing bacteraemia, gastroenteritis, urin
ary tract infections, neonatal meningitis, and peritonitis.1,9,10 In
addition, in the Consortium on Resistance against Carbapenems
in Klebsiella and other Enterobacterales (CRACKLE) studies, the
proportion of patients hospitalized with CRE who were admitted
from home increased over time.11,12
We have previously described 1040 unique patients hospita
lized in 49 US hospitals with CRE isolated from clinical cultures.11
Here, we explored possible community origins of CRE in a subset
of these patients. We compared characteristics between CRE that
were CA-CRE and those that were healthcare-associated (HA)
CRE.

Community-acquired CRE

Table 1. Patient characteristics with possibly community-associated CRE (CA-CRE) versus confirmed healthcare-associated CRE (HA-CRE)
Characteristic

HA-CRE (n = 208)

Total (n = 291)

34 (41)
25 (30)
18 (22)
6 (7)
64 (47–77)

105 (50)
45 (22)
36 (17)
22 (11)
65 (55–77)

139 (48)
70 (24)
54 (19)
28 (10)
65 (54–77)

44 (53)
39 (47)
16 (19)

114 (55)
94 (45)
19 (9)

158 (54)
133 (46)
35 (12)

P value
0.24

33 (40)
27 (33)
11 (13)
12 (14)
7 (4–12)
1 (0–3)
2 (0–3)

97 (47)
65 (31)
26 (12)
20 (10)
15 (7–29)
3 (1–5)
4 (2–6)

130 (45)
92 (32)
37 (13)
32 (11)
12 (6–23)
3 (1–4)
3 (2–6)

54 (65)
10 (12)
6 (7)
6 (7)
7 (8)
30 (36)
23 (28)

52 (25)
35 (17)
18 (9)
84 (40)
19 (9)
86 (41)
28 (13)

106 (36)
45 (15)
24 (8)
90 (31)
26 (9)
116 (40)
51 (18)

3 (4)
2 (2)
55 (66)
18 (22)
4 (5)
1 (1)
5 (6)
8 (10)
34/78 (44)

53 (25)
10 (5)
25 (12)
69 (33)
38 (18)
13 (6)
55 (26)
71 (34)
59/145 (41)

56 (19)
12 (4)
80 (27)
87 (30)
42 (14)
14 (5)
60 (21)
79 (27)
93/223 (42)

58 (70)
19 (23)
1 (1)
5 (6)

66 (32)
45 (22)
42 (20)
55 (26)

124 (43)
64 (22)
43 (15)
60 (21)

0.59
0.78

0.02
0.76

<0.001
<0.001
<0.001
<0.001

0.41
<0.01
<0.001

<0.001
<0.001
0.69

Values shown are n (%) unless indicated otherwise.
a
Other races include Native Hawaiian or Pacific islander (n = 2), Asian (n = 29) and multiracial (n = 69).

since absence of several comorbid conditions is part of the
CA-CRE definition, the Charlson comorbidity index was lower in
patients with CA-CRE (median 1, IQR 0–3) versus HA-CRE (median
3, IQR 1–5), P < 0.001. Patients with CA-CRE had shorter postculture hospital stays (median 7 days, IQR 4–12 days versus
15 days, IQR 7–29 days, P < 0.001) and lower acuity of illness
on the day of positive culture (median Pitt bacteraemia score 2,
IQR 0–3 versus 4, IQR 2–6, P < 0.001) than those with HA-CRE.
Overall, mortality of patients with CA-CRE was significantly lower

as compared with patients with HA-CRE at 30 days (6% versus
26%, P < 0.001) and at 90 days (10% versus 34%, P < 0.001).
Inverse probability weighting (IPW)-adjusted DOOR analysis
showed that a randomly selected patient with CA-CRE had a
66% (95% CI 56%–78%) chance of a better overall outcome as
compared with a patient with HA-CRE (Table 1). Similar differ
ences were observed in the subset of patients with infections
for unadjusted DOOR probabilities (69%, 95% CI 59%–78%),
and for mortality at 30 days (10% versus 35%, P < 0.001) and
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Region
Northeast
South
Midwest
West
Age, years, median (IQR)
Gender
Male
Female
Hispanic or Latino ethnicity
Race
White
Black
Othera
Unknown
Post-culture length of hospital stay, days, median (IQR)
Charlson comorbidity score, median (IQR)
Pitt bacteraemia score, median (IQR)
Culture source
Urine
Wound
Blood
Respiratory
Other
Infection
Community hospital
Disposition after discharge
Death
Hospice
Home
Long-term care
Long-term acute care
Transfer to other hospital
30 day mortality
90 day mortality
90 day readmission
DOOR at 30 days
Alive without events
Alive with one event
Alive with two or three events
Dead

CA-CRE (n = 83)

Shrestha et al.

90 days (10% versus 42%, P < 0.001). Of note, 90 day readmis
sion rates in patients discharged alive were similarly high in pa
tients with CA-CRE (34/78, 44%) and patients with HA-CRE (59/
145, 41%), P = 0.69.

Microbiology
The most common carbapenemase genes in both groups were
blaKPC-2 and blaKPC-3, which were found in 94% (214/227) of
carbapenemase-producing Enterobacterales (Table 2). No dif
ference in carbapenemase gene distribution was noted be
tween CA-CRE and HA-CRE. Species distribution was similar
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between CA-CRE and HA-CRE (Table 2). Seventy percent of
CRE isolates were K. pneumoniae (204/291), of which 66%
(135/204) belonged to ST258. ST258 was similarly common
in CA-carbapenem-resistant K. pneumoniae (CRKP) (36/60,
60%) and HA-CRKP (98/144, 68%). Carbapenemase genes
were present in 90% of CRKP (184/204). In non-K. pneumoniae
CRE, carbapenemase genes were present in 43/87 (49%) iso
lates; blaKPC-2 (n = 15) and blaKPC-3 (n = 22) were most common
ly encountered. ST131 (n = 15, 68%) was the most common
genetic lineage in E. coli, and four ST131 E. coli were CA-CRE.
Five of 41 (12%) Enterobacter isolates were ST171 E. cloacae,
of which four were CA-CRE.
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Figure 1. Flow diagram.

Community-acquired CRE

Table 2. Bacterial characteristics of possibly community-associated CRE
(CA-CRE) and confirmed healthcare-associated CRE (HA-CRE) isolates

Characteristic

HA-CRE
(n = 208)

Total
(n = 291)

60 (72)
36 (43)
4 (5)
3 (4)
12 (14)
4 (5)
8 (10)
4 (5)
0 (0)
3 (4)
67 (81)

144 (69)
98 (48)
6 (3)
3 (1)
29 (14)
1 (0)
14 (7)
11 (5)
10 (5)
11 (5)
160 (77)

204 (70)
134 (46)
10 (3)
6 (2)
41 (14)
5 (2)
22 (8)
15 (5)
10 (3)
14 (5)
227 (78)

37 (45)
22 (27)
5 (6)
4 (5)

82 (39)
75 (36)
0
5 (2)

119 (41)
97 (33)
5 (2)
9 (3)

P value
0.28

0.48

Data shown are n (%) unless otherwise indicated.
Klebsiella aerogenes (n = 6), Klebsiella michiganensis (n = 3), Klebsiella
oxytoca (n = 1).
b
Serratia marcescens (n = 5), Citrobacter freundii (n = 4), Raoultella ornithi
nolytica (n = 2), Citrobacter freundii (n = 1), Hafnia paralvei (n = 1),
Providencia stuartii (n = 1).
c
Counts exceed 100%, as three isolates carried two different carbapene
mase genes.
d
blaKPC-4 (n = 2), blaOXA-232 (n = 4), blaNDM-7 (n = 1), blaVIM-2 (n = 1), blaSME-2
(n = 1), blaOXA-181 (n = 1).
a

Figure 2. Maximum likelihood phylogenetic tree of carbapenemaseproducing Klebsiella pneumoniae (n=184). DOOR outcomes (1) alive with
out events, (2) alive with 1 event, (3) alive with 2 or 3 events, or (4) death.

Molecular epidemiology of carbapenemase-producing
K. pneumoniae
The population structure of 184 CPKP [53 (29%) CA-CPKP and 131
(71%) HA-CPKP] is shown in Figure 2. In CPKP, 131 (71%) strains
belonged to ST258, and a total of 27 K-loci types were present.
Most ST258 CPKP isolates had either KL107 (64/128, 50%),
KL106 (38/128, 30%), or KL51 (14/128, 11%). All ST307 isolates
had KL102 (10/10, 100%). Six ST15 CPKP strain were found, three
of these were CA-CPKP. The O-locus O2v2 was present in 86/184
(47%) CPKP isolates; 74/131 (56%) ST258 carried O2v2 versus 12/
53 (23%) of non-ST258 isolates (P < 0.001). CA-CPKP and HA-CPKP
had a similar distribution of K-loci and O-loci. In total, 113 CPKP
belonged to 31 clusters; 26/53 (49%) of CA-CPKP and 87/131
(66%) of HA-CPKP. 16/31 (52%) of clusters contained only
HA-CPKP strains (n = 47), 14 clusters contained both CA-CPKP
(n = 26) and HA-CPKP (n = 40), and a single cluster contained
two CA-CPKP isolates.

Bacterial genetic analysis
Bacterial genetic markers previously reported to be potentially
associated with colonization were selected based on literature
review (Table S1). Results of random forest modelling are shown

in Figure 3. The top three genetic markers associated with highest
mean decreases in Gini coefficient and accuracy over 10 separate
models were kpi_SA15, kpfC, and fimE. The kpi_SA15 operon was
more commonly present in CA-CPKP isolates (9/53, 17%) as com
pared with HA-CPKP (8/131, 6%), P = 0.026. kpfC was less com
monly present in CA-CPKP isolates (46/53, 87%) as compared
with HA-CPKP (127/131, 97%), P = 0.015. No difference in distribu
tion of fimE between CA-CPKP (48/53, 91%) and HA-CPKP (121/
131, 92%) was observed.

Discussion
Overall, we found that 10% of patients hospitalized with CRE re
presented community-associated cases. Our estimates of
CA-CRE varied geographically and between participating hospi
tals in the same region. A rise in CA-CRE infections has been ob
served in other regions of the world.1,18,19 An international
scoping review of CRE in the community reported estimates of
CA-CRE proportion ranging from 0%–30%.20 In the four
US-based studies included in this review, estimates ranged
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Species
Klebsiella pneumoniae
ST258
ST307
ST15
Enterobacter spp.
ST171 E. cloacae
Escherichia coli
ST131
Other Klebsiella spp.a
Otherb
Carbapenemase
presentc
blaKPC-2
blaKPC-3
blaNDM-1
Otherd

CA-CRE
(n = 83)

Shrestha et al.

between 5.6% and 10.8%, consistent with our findings.21–24
These studies were conducted between 2008–13 and used vari
ous methods and definitions of CA-CRE to arrive at their esti
mates.21–24 Between 2012 and 2017, rates of CRE cases in the
US have been stable and there has been no indication of wide
spread community transmission of CRE in the US.25 However,
early recognition of CRE strains that may contribute to future
community spread is of the utmost importance. A shift from pre
dominantly healthcare-associated to community-acquired in
fections in the epidemiology of CRE would have a dramatic
impact on our society through lives lost, increased healthcare
costs, and increased antibiotic usage.
We observed several clinical differences between patients
with CA-CRE and HA-CRE. This was expected, as our definition
for CA-CRE not only selects for higher likelihood of community ac
quisition, but also for a healthier population with fewer comorbid
conditions. The differences in outcomes including all-cause mor
tality, post-culture length-of-stay, and DOOR outcomes are most
likely primarily related to host factors, rather than to reduced
pathogenicity of CA-CRE. Surprisingly, rates of readmission were
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similarly high in patients with CA-CRE when compared with pa
tients with HA-CRE. This may be a consequence of the impact
of the detection of CRE in clinical cultures, which is known to pre
dispose to subsequent CRE infections.26
In E. coli, we specifically looked for and found several CA-CRE
isolates belonging to ST131. However, we did not find evidence
that ST131 was overrepresented in the CA-CRE cohort. ST131
E. coli is a worldwide-distributed high-risk strain that is frequently
associated with urinary tract infections and bacteraemia.27
Multiple reports of household and pet-to-human transmission
of ST131 E. coli have been reported.27 Our cohort is limited as
an evaluation of the impact of ST131 E. coli in community spread
of CRE in the US, as only 22 patients with E. coli were included.
While also limited by small numbers, we observed a numerical
overrepresentation of ST171 E. cloacae in CA-CRE strains. ST171
has been previously identified as a high-risk CRE clone associated
primarily with KPC-3 that is emerging in the US.28 Both ST131
E. coli and ST171 E. cloacae have the potential to cause increasing
numbers of CA-CRE infections in the future. Monitoring these
strain types going forward is warranted.
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Figure 3. Results of random forest modelling. Boxes indicate the first and third quartile, line indicates the median, and whiskers indicate the minimum
and maximum. Results shown for each genetic marker from 10 random forest models. (a) Decrease in mean Gini coefficient. (b) Decrease in mean
accuracy.

Community-acquired CRE

Limitations
This study has several limitations. First, as a secondary analysis of
the CRACKLE-2 cohort, defining CA cases was limited to the avail
able clinical variables that may have misclassified some isolates.
Documentation on prior hospitalizations, emergency room visits,
and long-term care stays outside the study period was unavail
able. For instance, it is possible that a patient admitted from
home had a recent hospitalization or long-term care stay during
which CRE was acquired. It is therefore likely that we overesti
mated true community acquisition of CRE. Second, our definition
for CA-CRE excludes patients with a history of several clinical co
morbidities indicative of healthcare exposures. Thus, it is not sur
prising that improved clinical outcomes were observed in
patients with CA-CRE, including DOOR outcomes and survival.
Third, associations with bacterial genetic markers should be con
sidered hypothesis-generating. Future studies are required to de
termine whether any of the bacterial characteristics we identified
are truly associated with CA-CRE.

Conclusions
In summary, community spread of CRE was limited during the
study period with approximately 10% of patients meeting cri
teria for community acquisition. True community acquisition
likely occurred only in a subset of these 10% of patients with
CRE. Several high-risk strain types were identified within the
CA-CRE cohort. Understanding the epidemiology of CA-CRE
and at-risk people for carriage of CA-CRE strains will assist
with measures to control AMR spread and early detection of
community spread of CRE.

Acknowledgements
The investigators would like to thank all the patients and their families.

Members of the MDRO Network Investigators
Investigators are listed by centre alphabetically. Albert Einstein College
of Medicine, Bronx, New York, USA: Gregory Weston, Belinda
Ostrowsky; Boston University, Boston, Massachusetts, USA: Judith
J. Lok; Case Western Reserve University, Cleveland, Ohio, USA: Robert
A. Bonomo, T. Nicholas Domitrovic, Kristine M. Hujer, Andrea M. Hujer,
Susan D. Rudin, Steven H. Marshall, Robert A. Salata, Federico Perez;
Cleveland Clinic, Cleveland, Ohio, USA: Eric Cober, Sandra S. Richter;
Duke Clinical Research Institute: Rebekka Arias, Carol Hill; Duke
University, Durham, North Carolina, USA: Vance G. Fowler Jr., Deverick
J. Anderson; Emory University, Atlanta, Georgia, USA: Jesse T. Jacob;
Fudan University, Shanghai, China: Minggui Wang; Hackensack
Meridian Health, Nutley, New Jersey, USA: Liang Chen, Samit Desai,
Barry N. Kreiswirth, Claudia Manca, Jose R. Mediavilla; Icahn School of
Medicine at Mount Sinai, New York, New York, USA: Gopi Patel; Mayo
Clinic, Rochester, Minnesota, USA: W. Charles Huskins, Robin Patel;
Medical College of Wisconsin and Froedtert Memorial Lutheran
Hospital, Milwaukee, Wisconsin, USA: Sara Revolinski; MedStar
Washington Hospital Center, Washington, District of Columbia, USA:
Glenn Wortmann; MetroHealth Medical Center, Cleveland, Ohio, USA:
Robert C. Kalayjian; North Shore University Hospital, Manhasset,
New York, USA: Angela Kim; Ochsner Clinic Foundation, New Orleans,
Louisiana, USA: Julia Garcia-Diaz; Stony Brook University, Stony Brook,
New York, USA: Bettina C. Fries; SUNY Downstate Medical Center,
New York, New York, USA: Brandon Eilertson; Temple University School
of Pharmacy, Philadelphia, Pennsylvania, USA: Jason C. Gallagher; The
George Washington University, Rockville, Maryland, USA: Michelle
Earley, Scott Evans, Lauren Komarow; University of California, Los
Angeles, California, USA: Omai B. Garner; University of California
San Francisco, San Francisco, California, USA: Henry F. Chambers;
University of Illinois College of Medicine at Peoria, Peoria, Illinois, USA:
John J. Farrell; University of Miami Miller School of Medicine and
Jackson Health System, Miami, Florida, USA: Lilian M. Abbo; University
of Michigan, Ann Arbor, Michigan, USA: Keith S. Kaye; University of
North Carolina, Chapel Hill, North Carolina, USA: Courtney Luterbach,
David van Duin; University of Pennsylvania, Philadelphia, Pennsylvania,
USA: Jennifer H. Han; University of Pittsburgh, Pittsburgh, Pennsylvania,
USA: Yohei Doi; University of Queensland, Queensland, Australia: David
L. Paterson; University of Southern California, Los Angeles, California,
USA: Darren Wong; University of Texas Health Science Center at
Houston, Houston, Texas, USA: Cesar A. Arias, Blake Hanson, An Dinh,
Diana Panesso, William Shropshire, Truc T. Tran; Vanderbilt University,
Nashville, Tennessee, USA: Ritu Banerjee; Wayne State University,
Detroit, Michigan, USA: Sorabh Dhar; Weill Cornell Medicine, New York,
New York, USA: Michael J. Satlin; Yale School of Medicine, New Haven,
Connecticut, USA: Matthew Grant.

2769

Downloaded from https://academic.oup.com/jac/article/77/10/2763/6649010 by Henry Ford Hospital - Sladen Library user on 13 October 2022

As most patients in our cohort had carbapenemase-producing
K. pneumoniae, we focused our in-depth genetic analyses on this
subgroup. CA-CRE and HA-CRE were mixed throughout the popu
lation structure of CRE in this cohort, and we found no evidence
for a single clone accounting for most of the community trans
mission. Several clusters were identified, including clusters that
included both patients with CA-CRE and HA-CRE implying possible
intra-hospital transmission of CA-CRE isolates to hospitalized pa
tients. We hypothesized that the ability of bacteria to successfully
colonize hosts with a relatively normal gut microbiome is one of
the requirements for successful community spread. Therefore,
we selected bacterial genetic markers a priori that had previously
been reported to be potentially associated with colonization by
K. pneumoniae. These included genes encoding type 1 (fim)
and type 3 (mrk) pili, as well as other fimbriae operons. fim and
mrk are the best described chaperone/usher systems encoding
genes resulting in assembly of type 1 and type 3 fimbriae.29,30
fimE and fimB control phase-switching of type 1 fimbriae, and
absence of fimE results in overexpression of type 1 fimbriae.31
It is unclear why fimE was identified as an important variable in
random forest modelling as no numeric differences were found
in positivity rates for fimE between CA-CPKP and HA-CPKP strains.
In random forest analysis, a high relative importance may be a
consequence of interactions with other variables. Therefore, ab
sence of fimE may be important for the CA phenotype only in
the setting of other specific genetic markers. The presence of
the kpi_SA15 operon was associated with CA-CRE phenotype in
our cohort. This should be considered a hypothesis-generating find
ing. The kpi_SA15 operon contains four genes that encode compo
nents of a different chaperone/usher system.32,33 However, little is
known about the functional importance of this system. kpfC en
codes the usher component of the kpf chaperone–usher system.
kpfR is a negative regulator of the kpf system.34 A kpfR knock-out
K. pneumoniae strain exhibited enhanced biofilm formation, but
decreased capsule production.34 The associations between the
CA phenotype and the kpi_SA15 operon and kpfC should be fur
ther evaluated in future studies. Of these, the kpi_SA15 operon is
of higher interest given the positive association with community
spread and prior studies.
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